Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Hughes, Andrew; Daniel, Susan E.; Kilford, L; Lees, Andrew J.

doi:10.1136/jnnp.55.3.181

Cited by 9,167 publications

(6,258 citation statements)

References 15 publications

Supporting

Mentioning

6,069

Contrasting

Unclassified

144

Order By: Relevance

“…Full clinical details of this cohort have been described previously 14. In brief, patients with idiopathic PD diagnosed within 3.5 years according to UK PD Society Brain Bank diagnostic criteria15 were recruited between September 2010 and September 2014 from a 2.9 million population (ethics study 10/H0505/71). Mean disease duration among 20 PD patients was 1.6 ± 1.1 years (range 0.1–3.2 years) and Hoehn and Yahr stage 1.9 ± 0.4 (range: 1–3, maximum possible score 5).…”

Section: Methodsmentioning

confidence: 99%

Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies

Fairfoul

McGuire

Pal

et al. 2016

Ann Clin Transl Neurol

399

257

View full text Add to dashboard Cite

We have developed a novel real‐time quaking‐induced conversion RT‐QuIC‐based assay to detect alpha‐synuclein aggregation in brain and cerebrospinal fluid from dementia with Lewy bodies and Parkinson's disease patients. This assay can detect alpha‐synuclein aggregation in Dementia with Lewy bodies and Parkinson's disease cerebrospinal fluid with sensitivities of 92% and 95%, respectively, and with an overall specificity of 100% when compared to Alzheimer and control cerebrospinal fluid. Patients with neuropathologically confirmed tauopathies (progressive supranuclear palsy; corticobasal degeneration) gave negative results. These results suggest that RT‐QuiC analysis of cerebrospinal fluid is potentially useful for the early clinical assessment of patients with alpha‐synucleinopathies.

show abstract

Section: Methodsmentioning

confidence: 99%

Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies

Fairfoul

McGuire

Pal

et al. 2016

Ann Clin Transl Neurol

399

257

View full text Add to dashboard Cite

show abstract

“…Per inclusion criteria, RBD subjects did not have parkinsonism19 or DLB20 at the time of the study. Participants with a history of psychotropic medication use before the onset of RBD were excluded 21…”

Section: Methodsmentioning

confidence: 99%

“…For reference, we studied the 18 F‐FDG‐PET scans of retrospectively‐included patients with clinical diagnoses of “probable PD” (n = 20, nondemented, aged 67.5 ± 8.6 years; 16 men; median disease duration, 2 years; interquartile range, 1‐7 years) and “probable DLB” (n = 22, aged 73.7 ± 7 years; 17 men; median disease duration, 3 years; interquartile range, 1‐4 years) according to consensus criteria 19, 20…”

Section: Methodsmentioning

confidence: 99%

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

et al. 2017

View full text Add to dashboard Cite

BackgroundIdiopathic REM sleep behavior disorder is a prodromal stage of Parkinson's disease and dementia with Lewy bodies. Hyposmia, reduced dopamine transporter binding, and expression of the brain metabolic PD‐related pattern were each associated with increased risk of conversion to PD. The objective of this study was to study the relationship between the PD‐related pattern, dopamine transporter binding, and olfaction in idiopathic REM sleep behavior disorder.MethodsIn this cross‐sectional study, 21 idiopathic REM sleep behavior disorder subjects underwent 18F‐fluorodeoxyglucose PET, dopamine transporter imaging, and olfactory testing. For reference, we included 18F‐fluorodeoxyglucose PET data of 19 controls, 20 PD patients, and 22 patients with dementia with Lewy bodies. PD‐related pattern expression z‐scores were computed from all PET scans.ResultsPD‐related pattern expression was higher in idiopathic REM sleep behavior disorder subjects compared with controls (P = 0.048), but lower compared with PD (P = 0.001) and dementia with Lewy bodies (P < 0.0001). PD‐related pattern expression was higher in idiopathic REM sleep behavior disorder subjects with hyposmia and in subjects with an abnormal dopamine transporter scan (P < 0.05, uncorrected).ConclusionPD‐related pattern expression, dopamine transporter binding, and olfaction may provide complementary information for predicting phenoconversion. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

show abstract

“…± 7.2 (range 50 to 84) years, and 29 control non-PD and cognitively normal subjects (16 men and 13 women), mean age 66.8±10.9 (range 50 to 84) years. PD subjects met the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria (Hughes et al, 1992). The diagnosis of PD was confirmed by the presence of nigrostriatal dopaminergic denervation as revealed by ( + )-[ 11 C]dihydrotetrabenazine vesicular monoamine type 2 (VMAT2) PET.…”

Section: Subjects and Clinical Test Batterymentioning

confidence: 99%

Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia

Bohnen

Müller

Kotagal

et al. 2012

J Cereb Blood Flow Metab

154

171

View full text Add to dashboard Cite

Parkinson's disease (PD) is a multisystem neurodegenerative disorder. Heterogeneous clinical features may reflect heterogeneous changes in different brain regions. In contrast to the pronounced nigrostriatal denervation characteristic of PD, cholinergic changes are less marked. We investigated cholinergic innervation activity in PD subjects relative to normal subjects. Nondemented PD subjects (n = 101, age 65.3±7.2 years) and normal subjects (n = 29, age 66.8 ± 10.9 years) underwent clinical assessment and [ 11 C]methyl-4-piperidinyl propionate acetylcholinesterase and [ 11 C]dihydrotetrabenazine monoaminergic positron emission tomography (PET) imaging. Cholinergic projection changes were heterogeneous for 65 out of 101 PD subjects who had neocortical and thalamic acetylcholinesterase activity within the normal range. The remainder had combined neocortical and thalamic (13/101), isolated neocortical (18/101), or isolated thalamic (5/101) acetylcholinesterase activity below the normal range. The low neocortical acetylcholinesterase activity subgroup had significantly lower global cognitive performance compared with the normal range subgroup (F = 7.64, P = 0.0069) with an independent effect for nigrostriatal denervation (F = 7.60, P = 0.0074). The low thalamic acetylcholinesterase activity subgroup did not differ from the normal thalamic acetylcholinesterase activity subgroup in cognitive performance or motor impairments except for a history of falls (P = 0.0023). Cholinergic denervation is heterogeneous with reduced neocortical and/or thalamic acetylcholinesterase activity in 36% of nondemented PD subjects with corresponding clinical phenotypic variation. Results also show independent cognitive effects for both cholinergic and dopaminergic system changes in nondemented PD subjects.

show abstract

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Cited by 9,167 publications

References 15 publications

Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies

Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia

Contact Info

Product

Resources

About